Diversified Trust Co Sells 2,426 Shares of Cencora, Inc. $COR

Diversified Trust Co decreased its position in Cencora, Inc. (NYSE:COR) by 5.4% during the 3rd quarter, HoldingsChannel reports. The fund owned 42,796 shares of the company’s stock after selling 2,426 shares during the quarter. Diversified Trust Co’s holdings in Cencora were worth $13,375,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the company. Norges Bank bought a new stake in shares of Cencora in the second quarter worth $695,215,000. Artisan Partners Limited Partnership acquired a new stake in Cencora in the 2nd quarter valued at $411,888,000. Vanguard Group Inc. lifted its position in Cencora by 5.3% during the 2nd quarter. Vanguard Group Inc. now owns 22,479,041 shares of the company’s stock worth $6,740,340,000 after buying an additional 1,125,661 shares in the last quarter. Viking Global Investors LP lifted its position in Cencora by 95.0% during the 2nd quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock worth $624,207,000 after buying an additional 1,013,913 shares in the last quarter. Finally, Ameriprise Financial Inc. boosted its stake in shares of Cencora by 228.6% during the 2nd quarter. Ameriprise Financial Inc. now owns 974,505 shares of the company’s stock worth $292,207,000 after buying an additional 677,952 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Stock Down 0.3%

COR opened at $340.08 on Tuesday. Cencora, Inc. has a 1-year low of $223.92 and a 1-year high of $377.54. The stock’s fifty day simple moving average is $348.91 and its 200 day simple moving average is $315.59. The company has a current ratio of 0.90, a quick ratio of 0.55 and a debt-to-equity ratio of 4.32. The stock has a market cap of $65.97 billion, a PE ratio of 42.78, a price-to-earnings-growth ratio of 1.62 and a beta of 0.63.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, topping analysts’ consensus estimates of $3.79 by $0.05. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The firm had revenue of $83.73 billion during the quarter, compared to analysts’ expectations of $83.36 billion. During the same period in the previous year, the business posted $3.34 earnings per share. The company’s revenue for the quarter was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, research analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 14th were paid a $0.60 dividend. This is an increase from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date was Friday, November 14th. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. Cencora’s dividend payout ratio (DPR) is currently 30.19%.

Insider Buying and Selling at Cencora

In other Cencora news, EVP Elizabeth S. Campbell sold 3,351 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the completion of the sale, the executive vice president directly owned 23,891 shares in the company, valued at $8,173,111.10. This trade represents a 12.30% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Robert P. Mauch sold 5,097 shares of the company’s stock in a transaction that occurred on Monday, October 20th. The shares were sold at an average price of $326.80, for a total value of $1,665,699.60. Following the completion of the transaction, the chief executive officer directly owned 37,940 shares in the company, valued at $12,398,792. The trade was a 11.84% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 20,317 shares of company stock valued at $7,009,260 in the last three months. 10.80% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Cencora in a research report on Monday, December 22nd. Wall Street Zen lowered Cencora from a “buy” rating to a “hold” rating in a research report on Friday, November 28th. Evercore ISI set a $400.00 price objective on Cencora and gave the company an “outperform” rating in a report on Thursday, November 6th. TD Cowen boosted their target price on shares of Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Finally, Robert W. Baird set a $392.00 price target on shares of Cencora in a research report on Tuesday, December 16th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, Cencora currently has an average rating of “Moderate Buy” and an average price target of $373.25.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.